Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical : Organizational Changes

10/22/2021 | 04:34am EST

Organizational Changes

TOKYO, October 22, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced the following organizational changes, effective January 1, 2022.

1. Establishment of Digital Transformation Unit

  • Digital Transformation Unit will be newly established to reorganize the digital and IT functions. Digital and IT Supervisory Div. will be abolished accordingly.
  • Digital Strategy Dept. and IT Solutions Dept., both currently exist under Digital and IT Supervisory Div., will be transferred to Digital Transformation Unit.

[Overview]

By reorganizing the digital and IT functions as a unit, Digital Transformation Unit will further promote company-wide digital and IT strategies. By deeply involved in individual IT and Digital projects, the Unit will accumulate and deploy knowledge, enhance governance and contain costs so that the company may accelerate the realization of digital transformation (DX), one of the key drivers in TOP I 2030.

2. Reorganization of Drug Safety Div. and Quality and Regulatory Compliance Unit

  • Safety Strategy Dept. will be renamed Safety Science Dept., and Pharmacovigilance Dept. will be renamed Drug Safety Data Management Dept. This is to strengthen the safety science and data management functions by clarifying the roles of each function.
  • The data science functions spread across each department will be reorganized as follows:
    • Planning and analysis relating to safety strategy: Safety Science Dept.
    • Surveillance management and solution provision: Risk Communication Dept.
  • Basic business operations of each department and functions related to DX will be consolidated in Drug Safety Coordination Dept. To achieve both quality and efficiency in quality management, reorganization with Quality & Regulatory Compliance Unit will be carried out.
  • Real World Data Science Dept. will be abolished, and its pharmacovigilance function will be transferred to other departments.

[Overview]

With RED SHIFT in mind, reorganization will take place to strengthen the safety science function and thereby ensure consistent and appropriate risk assessment and risk management of Chugai products from the early development stage to the post-marketing phase. The reorganization also aims to strategically and quickly utilize the data science function as it relates to real-world data including post-marketing surveillance.

RED: Research & Early Development

###

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 08:33:00 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/25CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
11/18CHUGAI PHARMACEUTICAL : Personnel Changes
PU
11/18CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
11/16CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
11/16Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index
AQ
11/16CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic P..
PU
11/16CHUGAI PHARMACEUTICAL : Hosted Discussion Series to Drive Quality Cancer Care in Developin..
PU
11/15CHUGAI PHARMACEUTICAL : Continuously Selected in the “DJSI World,” a Global ES..
PU
11/12TIMELINE : Toshiba's lurch from crisis to crisis since 2015
RE
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 975 B 8 604 M 8 604 M
Net income 2021 292 B 2 579 M 2 579 M
Net cash 2021 469 B 4 143 M 4 143 M
P/E ratio 2021 22,1x
Yield 2021 1,73%
Capitalization 6 454 B 56 933 M 56 954 M
EV / Sales 2021 6,14x
EV / Sales 2022 5,91x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3 925,00 JPY
Average target price 4 808,46 JPY
Spread / Average Target 22,5%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-28.68%56 933
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049